



Conference & Speaker Program



HOSTED BY:

A&IPS

Australasian Diabetes in Pregnancy Society

IADPSG

International Association
of the Diabetes and Pregnancy Study Groups

2022 **SYDNEY**
17-20 NOV
MEETING

Sheraton Grand • Sydney Hyde Park

TABLE OF CONTENTS

WELCOME.....	3
SCIENTIFIC STEERING COMMITTEE	3
LOCAL ORGANISING COMMITTEE	3
INFORMATION FOR DELEGATES AND PRESENTERS	4
Venue Directory.....	4
Registration Desk.....	4
Registration Inclusions	4
Welcome Reception	4
Conference Dinner	5
Speaker Preparation.....	5
Poster Presentations	5
iPhone/Android Conference Web-App	5
Wi-Fi.....	6
Special Meal Requests.....	6
Social Media	6
ADIPS Secretariat.....	6
INTERNATIONAL INVITED SPEAKERS	7
NATIONAL INVITED SPEAKERS	8
PROGRAM	9
Thursday 17 th November 2022	9
Friday 18 th November 2022	11
Saturday 19 th November 2022	14
Sunday 20 th November 2022	17
POSTER LISTING	19
SPONSOR & EXHIBITOR LISTING	24
NOTES	26

WELCOME

We warmly welcome you to the IADPSG meeting hosted by ADIPS in Sydney, Australia on November 18 - 20 2022. Leading clinicians and researchers in diabetes in pregnancy internationally will present the latest developments in the field. The meeting will be preceded by the "TOBOGM" Summit on November 17 which will present the landmark findings of the Treatment of Booking Gestational Diabetes Mellitus trial and its implications for the diagnosis of GDM.

As a hybrid meeting, we will be offering registrants the option to attend our meeting in person or virtually. IADPSG-ADIPS 2022 will provide the first opportunity to connect in person with your colleagues in more than two years. We look forward to seeing you soon!

Sincerely yours,

Arianne Sweeting

ADIPS President,

Chair IADPSG-ADIPS Scientific Steering Committee 2022

Fidelma Dunne

IADPSG Chair

SCIENTIFIC STEERING COMMITTEE

Arianne Sweeting	Christina Scifres
Fidelma Dunne	David Simmons
Ariane Godbout	Takashi Sugiyama
Alicia Jawerbaum	Vijayam Balaji
Robert Lindsay	

LOCAL ORGANISING COMMITTEE

Robyn Barnes	Dharmintra Pasupathy
Amanda Beech	David Simmons
Aunty Kerrie Doyle	Arianne Sweeting
Anna-Jane Harding	Tang Wong

INFORMATION FOR DELEGATES AND PRESENTERS

Venue Directory

Sheraton Grand Sydney Hyde Park

161 Elizabeth Street
Sydney, NSW, 2000
Ph: +61 2 9286 6000

Web address: www.iadpsg-adips2022.org

Location	Item
Grand Ballroom 1	TOBOGM Summit
Grand Ballroom 1	Sessions
Grand Ballroom 2	Exhibition, Poster Display, Catering



Registration Desk

Operation Times:

- Thursday 17th November 7:30am – 5:30pm
- Friday 18th November 7:45am – 6:00pm
- Saturday 19th November 8:15am – 5:30pm
- Sunday 20th November 8:15am – 6:00pm

All conference related enquires should be directed to ASN Events staff at this desk.

Onsite Conference Manager:

Jordyn Trolove
ASN Events
Email: jordyn.t@asnevents.net.au
Mobile: +61 488 121 355

Registration Inclusions

Delegates will receive the following goods and services as part of their registration:

- Access to the sessions of your choice
- Conference program booklet
- Morning tea, lunch and afternoon tea for the days of nominated attendance
- Ticket to the Welcome Function (booking required)
- Use of the conference app
- Complimentary Wi-Fi

Welcome Reception

The Welcome Reception will be held on Friday 18th November 2022 from 5:30pm to 7:00pm in Grand Ballroom II. Please see the registration desk to see if there are still places available.

Conference Dinner

The Conference Dinner is without a doubt a highlight of the 2022 Meeting. We will be celebrating our first face-to-face meeting since 2019 with some of the best views in Sydney at the Australian National Maritime Museum on Saturday 19th November 2022. Tickets can be purchased at the registration desk for \$100.

Venue: Australian National Maritime Museum

Dress Code: Smart Casual

Speaker Preparation

Presentations are to be uploaded by the AV Technician within Grand Ballroom I at least two hours prior to your session. You should bring your talk on a USB, saved in a format for display on a PC within the room. An AV technician will be available in the room to assist with transfer / loading issues.

Poster Presentations

There will be 2 dedicated poster sessions and we recommend standing with your work during this time to facilitate discussions.

- Poster Session One: Friday 18th November, 12:30pm – 1:30pm
- Poster Session Two: Saturday 19th November, 12:30pm – 1:30pm

Posters can be displayed from 10:30am on Friday 18th November and must be taken down after afternoon tea on Sunday 20th November. The approved way of attaching your poster is with Velcro, which will be provided on your poster board.

iPhone/Android Conference Web-App

The App is displayed in a simple and easy to read format on your phone, iPad, or computer. To get the 'App', please open the below link in your internet browser on your smart phone, iPad or laptop.

<http://iadpsg-2022-hosted-by-adips.m.asnevents.com.au>

You will be prompted to add an icon onto your device home screen. The 'App' will allow you to:

- View the full conference program
- View all abstracts for the conference
- Save your favourite sessions and plan your day
- Take notes which will then be saved and downloaded from your registration profile
- Participate in live polling during the sessions

To use most of these functions, you will be prompted to 'log in' each day. Simply enter the same email and password which you used to register.

Wi-Fi

Complimentary Wi-Fi is available for delegates within the conference areas for the duration of the conference. The Wi-Fi connection is suitable for the viewing of emails and browsing.

How to connect:

1. Please connect to the following Network: Marriott Bonvoy
2. When prompted, select 'Connect'

Special Meal Requests

If you have nominated a special meal (dietary requirements, vegetarian, etc.) please identify yourself to the hotel staff. All requests have been passed onto the hotel and will be catered for accordingly.

Social Media

We invite all Conference attendees to use the hashtag #IADPSG22 when posting about the Conference on social media. Adding #IADPSG22 to your post can help connect you with other attendees. Be sure to follow ADIPS on Twitter - https://twitter.com/ADIPS_SOC

ADIPS Secretariat



Suzie Neylon

Executive Officer | ADIPS Limited

M: 0433 458 405

Email: sneylon@adips.org | Web: www.adips.org

Address: 145 Macquarie Street, Sydney NSW 2000

INTERNATIONAL INVITED SPEAKERS



JANE ALSWEILER



HELENA BACKMAN



VIJAYAM BALAJI



ASHLEY BATTARBEE



KATRIEN BENHALIMA



FIONNUALA BREATHNACH



CAROLINE CROWTHER



FIDELMA DUNNE



AOIFE EGAN



DENICE FEIG



LORIE HARPER



WILLIAM HERMAN



TERI HERNANDEZ



RUTH HUGHES



ALICIA JAWERBAUM



SUSAN OZANNE



ANAND SHANKAR



LUIS SOBREVIA

NATIONAL INVITED SPEAKERS



ROBYN BARNES



WAH CHEUNG



ANAND HARDIKAR



RACHEL HICKS



LOUISE HULL



DAVID MCINTYRE



ANNA MCLEAN



GLYNIS ROSS



CARLOS SALOMON



RENUKA SHANMUGALINGAM



DAVID SIMMONS



ARIANNE SWEETING



JULIA ZINGA

PROGRAM

Thursday 17th November 2022

Registration Open

7:30AM - 5:30PM

Grand Ballroom 2

Welcome and Acknowledgement to Country

8:45AM - 9:00AM

Grand Ballroom 1

Chairs: Arianne Sweeting & Fidelma Dunne

Should we treat hyperglycaemia less than overt diabetes before 24 weeks gestation?

9:00AM - 10:00AM

Grand Ballroom 1

Chairs: Fidelma Dunne & Christina Scifres

9:00 AM

Katrien Benhalima

Where are we now? Global overview on the current screening practice and diagnostic criteria for gestational diabetes in early pregnancy. *abs# 1*

9:20 AM

Lorie Harper

What are the issues relating to screening, diagnosis and treatment of hyperglycaemia in early pregnancy? *abs# 2*

9:40 AM

David Simmons

Study design/sample handling/statistics *abs# 3*

Morning Tea

10:00AM - 10:20AM

Grand Ballroom 1

The TOBOGM study results

10:20AM - 12:30PM

Grand Ballroom 1

Chairs: Christopher Nolan & David Sacks

10:20 AM

David Simmons

Primary Outcomes of the TOBOGM Study *abs# 4*

10:45 AM

Helena Backman

How should we collect samples for glucose estimations Comparison of samples? TOBOGM sub-study *abs# 5*

11:00 AM

Rachel Hicks

Consumer perspectives on potential glycaemic thresholds *abs# 6*

11:15 AM

Arianne Sweeting

Options for glycaemic thresholds and glycaemic measures including from the TOBOGM study *abs# 7*

11:35 AM Panel Discussion: Katrien Benhalima, Lorie Harper, David Simmons, Helena Backman, Rachel Hicks, Arianne Sweeting

Lunch

12:30PM - 1:30PM Grand Ballroom 1

Workshop Session 1

1:00PM - 2:15PM Grand Ballroom 1

Chairs: Rosemary Hall & Boyd Metzger

Q1 - Should we test for and treat gestational diabetes from early pregnancy? What are the issues with/with not doing this?

Q2 - What diagnostic criteria should we use for GDM in early pregnancy? What are the issues with choosing criteria?

Workshop Session 2

2:15PM - 3:45PM Grand Ballroom 1

Chairs: Stephen Colagiuri & Teri Hernandez

Q3 - What are the issues over how we should screen for early GDM to decide who should have an OGTT?

Q4 - What are the challenges in nomenclature/classification for GDM in early pregnancy

Where to from here?

3:45PM - 4:30PM Grand Ballroom 1

Chairs: Jeremy Oats & Denice Feig

3:55 PM **Boyd Metzger** - Perspective from HAPO

4:00 PM **Balaji Vijayam** - Perspective from LMIC

4:05 PM **David McIntyre** - Perspective from FIGO

4:10 PM **Fidelma Dunne** - Perspective from IDF

Workshop Session 3

4:30PM - 5:00PM Grand Ballroom 1

Chairs: Jeremy Oats & Denice Feig

Registration Open

7:45AM - 6:00PM

Grand Ballroom 2

Opening Ceremony and Welcome to Country

8:45AM - 9:00AM

Grand Ballroom 1

Chairs: Arianne Sweeting & Fidelma Dunne

The significance of GDM in early pregnancy

9:00AM - 10:30AM

Grand Ballroom 1

Chair: Arianne Sweeting

9:00 AM

David Simmons

Gestational diabetes mellitus in the first half of pregnancy and the TOBOGM Summit: Where to from here? *abs# 8*

9:30 AM

Lorie Harper

Early Gestational Diabetes Screening in the Obese Gravida: A Randomized Controlled Trial *abs# 9*

10:00 AM

Balaji Vijayam

Rationale for Early Screening and Diagnostic in Indian population with Hyperglycemia in pregnancy *abs# 10*

Morning Tea & Exhibition

10:30AM - 11:00AM

Grand Ballroom 2

Basic science: Placenta and biomarkers in DIP

11:00AM - 12:30PM

Grand Ballroom 1

Chair: Alicia Jawerbaum & Helen Barrett

11:00 AM

Luis Sobrevia

Fetoplacental endothelium insulin/adenosine axis signalling in gestational diabetes *abs# 11*

11:30 AM

Carlos Salomon

Dynamic changes in circulating Extracellular vesicles and their role inducing alterations in maternal insulin sensitivity across gestational diabetes mellitus *abs# 12*

12:00 PM

Soumyalekshmi Nair

Associations between insulin resistance and extracellular vesicle-associated proteins and miRNAs in gestational diabetes mellitus *abs# 13*

12:10 PM

Soumyalekshmi Nair

Selective placental and adipose tissue miRNA sorting in extracellular vesicles in gestational diabetes mellitus *abs# 14*

Screening and diagnosis in GDM: Updates from recent trials

4:00PM - 5:30PM

Grand Ballroom 1

Chairs: Fidelma Dunne & William Lowe Jr

4:00 PM

Christina Scifres

One step vs two step screening for gestational diabetes: evidence from trials in the United States *abs# 25*

4:30 PM

Caroline A Crowther

Lower versus higher glycaemic criteria for the diagnosis and treatment of gestational diabetes. *abs# 26*

The session will conclude with a 30-minute panel discussion with Fidelma Dunne, William Lowe Jr, Christine Scifres and Caroline Crowther.

5:30 PM

Day 1 Program Concludes

Welcome Function

5:30PM - 7:00PM

Grand Ballroom 2

Registration Open

8:15AM - 5:30PM

Grand Ballroom 2

Current concepts in nutrition in diabetes in pregnancy

9:00AM - 10:30AM

Grand Ballroom 1

Chairs: Susan de Jersey & Anna-Jane Harding

9:00 AM

Teri L Hernandez

Expanding Nutrition Options in Gestational Diabetes Choosing Healthy Options in Carbohydrate Energy: The CHOICE Diet Story *abs# 27*

9:40 AM

Robyn Barnes

Is Medical Nutrition Therapy for GDM too Gluco-centric? *abs# 28*

10:10 AM

Julia Zinga

Food insecurity as a determinant of health for women with diabetes in pregnancy *abs# 29*

Morning Tea & Exhibition

10:30AM - 11:00AM

Grand Ballroom 2

Basic science: Biomarkers and fetal programming

11:00AM - 12:30PM

Grand Ballroom 1

Chairs: Robyn Barnes & Rosemary Hall

11:00 AM

Susan Ozanne

Obesity during pregnancy: a window of opportunity to improve the health of two generations *abs# 30*

11:30 AM

Alicia Jawerbaum

Maternal diets enriched in unsaturated fatty acids to prevent fetal programming in DIP *abs# 31*

12:00 PM

Anandwardhan Hardikar

microRNA biomarkers of diabetes in pregnancy *abs# 32*

ADIPS Annual General Meeting

12:30PM - 1:00PM

Grand Ballroom 1

All members welcome

Lunch, Exhibition & Poster Viewing

12:30PM - 1:30PM

Grand Ballroom 2

Free communication - rural and remote diabetes in pregnancy

1:30PM - 2:40PM

Grand Ballroom 1

Chair: Alexis Shub & Aunty Kerrie Doyle

1:30 PM

Diana MacKay

Improving systems of care for hyperglycaemia in pregnancy in regional and remote Australia *abs# 33*

1:40 PM

Matthew J.L. Hare

Trends in outcomes of pregnancies complicated by diabetes among First Nations and non-First Nations women in the Northern Territory, Australia *abs# 34*

1:50 PM

Anna J Wood

Early screening for gestational diabetes and birth outcomes among Aboriginal women in remote Northern Territory. *abs# 35*

2:00 PM

Margot Robinson

Obesity as a driver of preeclampsia in women with Type 2 Diabetes *abs# 36*

2:10 PM

Diana MacKay

Changes in birth outcomes following a multi-component health systems intervention for hyperglycaemia in pregnancy in Australia's Northern Territory *abs# 37*

2:20 PM

Marwan Ahmed

Overweight/obesity and other predictors of gestational diabetes among Aboriginal and non-Aboriginal women in Western Australia *abs# 38*

2:30 PM

David Simmons

Are there ethnic differences in the development of gestational diabetes mellitus across pregnancy? Results from the Treatment of Booking Gestational Diabetes Mellitus study *abs# 39*

Debate: Low dose aspirin should be initiated in early pregnancy for pre-eclampsia prevention in women with pre-gestational diabetes

2:40PM - 3:30PM

Grand Ballroom 1

Chair: Alexis Shub

Fionnuala Breathnach - Affirmative/PRO *abs# 40*

Renuka Shanmugalingam - Negative/CON *abs# 41*

Afternoon Tea & Exhibition

3:30PM - 4:00PM

Grand Ballroom 2

Clinical trials update

4:00PM - 5:30PM

Grand Ballroom 1

Chair: Christina Scifres & Julia Zinga

4:00 PM **Fidelma Dunne**
EMERGE: A Randomised Placebo-Controlled Trial of the effectiveness of Early Metformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects *abs# 42*

4:23 PM **Ashley Battarbee**
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) *abs# 43*

4:46 PM **Denice Feig**
MITY Kids *abs# 44*

Session sponsored by 

5:10 PM **Day 2 Program Concludes**

Conference Dinner

7:00PM - 11:00PM Australian National Maritime Museum
Delegates are required to source their own transport to/from the dinner. The museum is a 1.4km walk around Darling Harbour. 2 Murray St, Sydney NSW 2000

Registration Open

8:15AM - 6:00PM

Grand Ballroom 2

Technology in type 1 diabetes

9:00AM - 10:30AM

Grand Ballroom 1

Chairs: Sarah Price & Glynis Ross

9:00 AM

Denice Feig

Translating technology into clinical care *abs# 46*

9:30 AM

Katrien Benhalima

Update on closed loop systems in T1DM. *abs# 47*

10:00 AM

Anna McLean

Use of technology for Indigenous women with diabetes in pregnancy. *abs# 48*

Session sponsored by

Medtronic

Morning Tea & Exhibition

10:30AM - 11:00AM

Grand Ballroom 2

Therapies in diabetes in pregnancy

11:00AM - 12:30PM

Grand Ballroom 1

Chairs: Balaji Vijayam & Jeff Flack

11:00 AM

Anand Shankar

Insulin Analogues in Hyperglycaemia in Pregnancy - Indian Experience *abs# 49*

11:30 AM

Fidelma Dunne

Insulin Analogues in Pregnancy- The EXPECT randomized controlled trial *abs# 50*

12:00 PM

Jane M Alsweiler

Neonatal therapies for neonatal hypoglycaemia *abs# 51*

Session sponsored by



Lunch, Exhibition & Poster Viewing

12:30PM - 1:30PM

Grand Ballroom 2

Policy/translation

1:30PM - 3:30PM

Grand Ballroom 1

Chairs: David Simmons & N Wah Cheung

1:30 PM

David McIntyre

In the wake of HAPO *abs# 52*

1:54 PM

Glynis P Ross

Health system strategies in Australia to improve the Outcomes of Diabetes in Pregnancy *abs# 53*

2:18 PM

Helena Backman

National approach to diabetes in pregnancy and its management in Sweden *abs# 54*

2:42 PM

William H Herman

The Health Economics of Screening and Treatment for Gestational Diabetes *abs# 55*

3:06 PM

Rachel R Hicks

Consumer Perspectives of Diabetes and Pregnancy: how consumers and community shape and influence interventions for women with diabetes *abs# 56*

Afternoon Tea & Exhibition

3:30PM - 4:00PM

Grand Ballroom 2

Pre-and post-pregnancy care in DIP

4:00PM - 5:30PM

Grand Ballroom 1

Chairs: Amanda Beech & Janet Lagstrom

4:00 PM

Aoife M Egan

Pre-Pregnancy Care for Women with Diabetes *abs# 57*

4:30 PM

Mary Louise Hull

Post-Pregnancy Intervention and Fertility *abs# 58*

5:00 PM

N Wah Cheung

A Randomised Controlled Trial of Text-Messaging to Improve Lifestyle following Gestational Diabetes: Smart Mums with Smart Phones 2 *abs# 59*

Awards and Closing Ceremony

5:30PM - 6:00PM

Grand Ballroom 1

Chairs: Fidelma Dunne & Arianne Sweeting

6:00 PM

Day 3 Program Concludes

POSTER LISTING

Marwan Ahmed

Shoulder dystocia in Australian Aboriginal babies born to mothers with diabetes *abs# 80*

Tutangi Amataiti

Does Providing Fruit and Vegetables, or Supermarket Vouchers Increase Adherence to a Reduced Carbohydrate Diet in Women with Gestational Diabetes? *abs# 81*

Kensuke Ashimoto

Can self-monitoring of blood glucose measurements be discontinued during pregnancy? *abs# 82*

Helen L Barrett

Circulating beta-hydroxybutyrate levels in overweight and obese pregnant women at 28 weeks gestation are not associated with dietary carbohydrate *abs# 83*

Helen L Barrett

Women with Gestational Diabetes Mellitus with managed plasma glucose levels, exhibit dyslipidaemia that may contribute to fetal adiposity and warrants treatment *abs# 84*

Cellina Ching

The effect of COVID lockdown on physical activity in postpartum women with gestational diabetes *abs# 85*

Hannah E Christie

From Diagnosis to Delivery: Postprandial Walking as a Non-Pharmaceutical Treatment for Gestational Diabetes Mellitus. *abs# 86*

Suzette M Coat

Compliance with postpartum screening recommendations: an audit of a single site from the TOBOGM study *abs# 87*

Jennifer Conn

Pre-pregnancy planning in a woman with diabetes mellitus secondary to familial partial lipodystrophy type 3 *abs# 88*

Susan de Jersey

Modified gestational diabetes screening and testing criteria during the COVID-19 pandemic: what were the views of consumers and clinicians during this time? *abs# 89*

Daria Di Filippo

Oral glucose tolerance test and continuous glucose monitoring for gestational diabetes diagnosis: a survey study of women's and health care professionals' perception. *abs# 90*

Daria Di Filippo

Freestyle Libre Pro 2 for the diagnosis of gestational diabetes mellitus: a pilot study. *abs# 91*

Hillarie J Drever

Factors associated with higher risk of small-for-gestational-age infants in women treated for gestational diabetes *abs# 92*

Jade Eccles-Smith

Outcomes of pregnancies following bariatric surgery delivering 2013-2018 in Queensland: A data-linkage study *abs# 93*

Amelia Fernandes

The impact of preconception weight loss interventions on pregnancy outcomes in women with Polycystic Ovary Syndrome *abs# 94*

Cecily Foged

Does the method of insulin delivery impact the frequency of consultations during antenatal care for patients with Type 1 Diabetes Mellitus? *abs# 95*

Manxin Gao

Does bariatric surgery reduce the risk of obesity-related adverse pregnancy outcomes in women with gestational diabetes mellitus? – A retrospective cohort study. *abs# 96*

Reetu Gogna

Comparison of insulin requirements in women diagnosed with gestational diabetes on oral glucose tolerance test. *abs# 97*

Rosemary M Hall

Does a reduced carbohydrate diet in women with gestational diabetes optimise gestational weight gain and glucose control? *abs# 99*

Matthew Hare

Haemoglobin A1c screening in early pregnancy among Aboriginal women in remote communities of the Northern Territory, Australia *abs# 100*

Su Win Htike

Flash Glucose Monitoring – Heraldng Impaired Placental Flows with Glucometric Lows *abs# 101*

Su Win Htike

Is high dose insulin therapy in gestational diabetes (GDM) associated with adverse pregnancy outcomes? *abs# 102*

Emma L Jamieson

Hyperglycaemia in Pregnancy: A new paradigm for adverse perinatal outcome risk stratification *abs# 104*

Emma L Jamieson

Oral glucose tolerance test to diagnose gestational diabetes mellitus: impact of variations in specimen handling *abs# 105*

Alicia Jawerbaum

Fetal programming of impaired decidualization in the offspring of diabetic rats *abs# 106*

Lynda Jones

Neonatal Outcomes of a New Model of Care for Gestational Diabetes. *abs# 107*

Shantha Joseph

Peripartum glycemic management in women with pre-existing diabetes: Challenges and Opportunities *abs# 108*

Andrew Kirke

OGTT the imperfect gold standard: a qualitative study of rural and remote clinicians' experience

abs# 109

William Kovacevic

Glycaemic control and pregnancy outcomes in a multicultural cohort of women with type 1 diabetes

abs# 110

Cathy Latino

Excessive gestational weight gain in women with gestational diabetes is associated with less available Medical Nutritional Therapy: results from a tertiary maternity centre in Western Australia

abs# 111

Louis Levinzon

Combined HNF4A (MODY 1) and INSR mutations diagnosed in pregnancy: a case report and literature review

abs# 112

Elizabeth S Lewis-Hills

Ngā Hua o Te Kōpū: Indigenous research methodology for diabetes in pregnancy

abs# 113

Julia Marley

Prediabetes and pregnancy: A lower first trimester HbA_{1c} threshold of 5.6% identifies preconception prediabetes and high risk for adverse perinatal outcome

abs# 114

Simone L Marschner

Perception of Diabetes Risk Among Australian Women With Gestational Diabetes

abs# 115

Julia Unterscheider

Pre-gestational Diabetes and Pregnancy: What Obstetricians Need to Know

abs# 116

Julia Unterscheider

Gestational Diabetes: Are we Making a Mountain out of a Molehill?

abs# 117

Julia Unterscheider

Perinatal Mortality and Diabetic Pregnancy: Why Babies Die?

abs# 118

Nina Meloncelli

Insights from co-designing a dietary intervention to prevent gestational diabetes: woman-centred care and implications for clinicians

abs# 119

Yitayeh Mengistu

Models for predicting postpartum glucose intolerance among women with a history of gestational diabetes mellitus: a systematic review

abs# 120

Alisha Panambalana

Maternal characteristics and pregnancy outcomes of women diagnosed with gestational diabetes at an early oral glucose test

abs# 121

Sarah Price

Does substantial preconception weight loss in women with obesity modify the epigenetic signature of the offspring? A pilot study

abs# 122

Anam ASR Rai

Employing fasting plasma glucose to safely limit the use of oral glucose tolerance tests in pregnancy: a

pooled analysis of four Norwegian prospective studies with universal screening for gestational diabetes
abs# 123

Fahimeh Ramezani Tehrani

Fasting plasma glucose values 5.1-5.6 mmol/l in the first trimester of gestation
abs# 124

Gladys A Ramos

Comparison of point-of-care glucose values and continuous glucose monitor values in intrapartum patients with Type 1 diabetes
abs# 125

Sidsel Linneberg SLR Rathcke

The association between birthweight and maternal glycemic control in type 1 diabetes
abs# 126

Yoon Ji Jina Rhou

Pregnancy outcomes in pre-existing diabetes: A 10-year retrospective study
abs# 127

Christopher W Rowe

Adoption of a pregnancy-specific intravenous insulin protocol (Pregnancy-IVI) at a regional centre has equivalent safety and efficacy outcomes as a tertiary hospital
abs# 128

Hisanobu Sadakata

Insulin secretion and insulin resistance in patients with gestational diabetes mellitus diagnosed during earlier pregnancy.
abs# 129

Joanne M Said

PRECeDe Pilot: Prevention of neonatal Respiratory distress with antenatal corticosteroids prior to Elective Caesarean section in women with Diabetes - A Feasibility Randomised Trial
abs# 130

Joanne M Said

PRECeDe Pilot: Prevention of neonatal Respiratory distress with antenatal corticosteroids prior to Elective Caesarean section in women with Diabetes – Can we blind participants, clinicians and researchers in a placebo-controlled randomised trial?
abs# 131

Cathrine M Scheuer

Untreated gestational diabetes diagnosed by WHO2013-criteria is associated with high rates of adverse maternal and neonatal outcomes - a Danish cohort study
abs# 132

Salvatore F Sfameni

Screening for gestational diabetes mellitus and hyperglycemia in pregnancy with the glucose challenge test.
abs# 133

Anand Shankar

Association of poor foetal growth with Maternal Glucose-Insulin Adjustment Fail During Gestation
abs# 134

Anand Shankar

Hypovitaminosis D or Vitamin D deficiency may anticipate gestational diabetes
abs# 135

Roslyn A Smith

GDM outcomes during the COVID pandemic: an observational dietetic study
abs# 136

Erica P Spry

Implementation of fluoride-citrate tubes to stabilise glucose for detecting GDM in Kimberley Aboriginal Community Controlled Health Services: a mixed methods assessment. *abs# 138*

Tessa Weir

StUdy of Gestational diabetes And Risk using Electronic Data (SUGARED) *abs# 139*

Hannah Wesley

Prevalence of prediabetes and type 2 diabetes (T2D) during postpartum follow up of women with history of early pregnancy gestational diabetes mellitus (eGDM): A systematic review and meta-analysis *abs# 140*

Hannah Wesley

Early pregnancy gestational diabetes mellitus (eGDM): Prevalence and its risk factors compared to conventional gestational diabetes mellitus (cGDM) in south Asian Indian women *abs# 141*

Hiroshi Yamashita

Glucose values of diagnostic oral glucose tolerance test during pregnancy and perinatal and postnatal risk in lean Japanese women with gestational diabetes *abs# 142*

Lili Yuen

An Update in Methodology to the International Diabetes Federation Atlas Estimation of Hyperglycaemia in Pregnancy *abs# 143*

Xi May Zhen

Impact of Obesity on Pregnancy Outcomes in People with T2DM vs T1DM: A Retrospective Cohort Study *abs# 144*

SPONSOR & EXHIBITOR LISTING

Diabetes Australia

The National Diabetes Services Scheme (NDSS) is an initiative of the Australian Government, administered by Diabetes Australia. The NDSS provides access to support and information services, education, programs and subsidised products to assist people to self-manage their life with diabetes. Registration with the NDSS is free to all eligible individuals.

Ingham Institute for Applied Medical Research

The Ingham Institute's world-class medical research is driven by the needs of our local Southwest Sydney community. The Institute is committed to inspiring the better health of our local community and transforming the treatment and care of people living with common medical conditions and disease.

Through applied medical research and partnerships with universities, hospitals, and the community, the Ingham Institute is working to radically transform health outcomes for the better – creating thriving communities, locally and globally.

Medtronic

We lead global healthcare technology, boldly attacking the most challenging problems. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people, and our technologies transform the lives of two people every second, every hour, every day. Expect more from us.

Medtronic. Engineering the extraordinary.

Merck

Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 60,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.

Net-Health

Net-Health is a medical software company that was founded in Queensland, Australia over 15 years ago.

We offer an innovative application software, Net-HealthData, that serves as a decision support platform for medical professionals and diabetic patients, especially pregnant women with diabetes, through a home monitoring platform. Our platform is aimed to improve quality of life, decrease avoidable interventions, and empower patients to be proactive about their diabetic health data and monitoring. This will ensure peace of mind for the expectant mother and provide on-time patient care to the unborn child.

A GDM solution helping women actively participate in their diabetes care and health professionals can provide timely care and guidance. Net-HealthData is currently being used at more than 20 hospitals across Qld, Victoria, and South Australia.

Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries.

Company website: www.novonordisk.com.au

Company email: aunrccc@novonordisk.com

Address: Level 10, 118 Mount Street North Sydney NSW 2060

The Makers of the Omnipod® Insulin Management System

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. Focusing on simplicity, the Pod is a tubeless, waterproof insulin pump delivering non-stop insulin.

Ypsomed

Ypsomed Australia is the Australian arm of Ypsomed, a Swiss-based company with a deep heritage in the development and manufacture of injection and infusion systems for self-medication, including insulin therapy. With over 30 years' experience in bringing insulin-delivery devices to market, Ypsomed is sensitive to the physical and emotional challenges that people on insulin therapy face in their everyday life and is committed to making a difference through the design and delivery of quality products and support services that make life with diabetes easier.

NOTES

NOTES

NOTES

NOTES
